ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Kleiner Perkins Caufield & Byers has formed a new venture capital fund to back biotech and drug companies, government agencies, and universities developing products to address infectious diseases and pandemic preparedness. The $200 million KPCB Pandemic & Bio Defense Fund will over the next three years focus on innovation in surveillance and detection, diagnostics, vaccines, and drugs. The fund's first investment is in BioCryst Pharmaceuticals, which believes its drug candidate Peramivir, a viral neuraminidase inhibitor, could be effective in treating avian flu.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter